Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes of Initially Unresectable Hepatocellular Carcinoma Patients Receiving TACE/HAIC Plus Anti-Angiogenic Agents and Immune Checkpoint Inhibitors as Conversion Therapy, Achieving Complete Radiological Response or Resectability, Followed by Systemic Treatment or Surgical Resection: A Prospective Cohort Study

NCT07206511 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07206511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07206511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes of Initially Unresectable Hepatocellular Carcinoma Patients Receiving TACE/HAIC Plus Anti-Angiogenic Agents and Immune Checkpoint Inhibitors as Conversion Therapy, Achieving Complete Radiological Response or Resectability, Followed by Systemic Treatment or Surgical Resection: A Prospective Cohort Study
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
October 9, 2025
Completion date
December 31, 2028
Enrollment
278 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinom